TP53 and cancer: Kadioglu et al. (2018) tested the cytotoxicity of oridonin in spectrum of drug-resistant cancer cell lines including CCRF-CEM (leukemia, IC50: 1.65 μM), CEM/ADR5000 (leukemia, IC50: 8.53 μM), MDA-MB231 (breast carcinoma, IC50: 6.06 μM), MDA-MB231/BCRP (breast carcinoma, IC50: 9.74 μM), HCT116 (p53+/+) (IC50: 18.0 μM), HCT-116 (p53−/−) (IC50: 34.7 μM), U87MG (glioblastoma, IC50: 17.4 μM), HepG2 (liver carcinoma, IC50: 25.7 μM), and AML12 (liver normal cells, IC50: >109 μM) cells, but did not mention the incubation time with oridonin in these cytotoxic test experiments [28].